Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Fig. 3

Progression-free survival (PFS) (a, c, e) and overall survival (OS) (b, d, f) in melanoma patients receiving anti-PD-1 antibodies, who had skin/vitiligo/endocrine (a, b), and lung (c, d) irAEs and fatigue (e, f). The patients experiencing skin/vitiligo/endocrine irAEs had favorable PFS and OS but those who experienced fatigue and lung irAEs had unfavorable PFS and OS. The numbers below the charts correspond to patients at risk at each time point. irAE, immune-related adverse events

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us